This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate MT
CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CI
CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
CUREVAC : Significant cash drain in the Q1 Alphavalue
Health Care Up as Vaccine Makers Gain - Health Care Roundup DJ
CUREVAC : A missed opportunity Alphavalue
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 MT
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CureVac Begins Early Stage Portion of Investigational Vaccine Trial MT
CureVac Hires New Chief Business Officer MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate MT
Transcript : CureVac N.V., Q4 2023 Earnings Call, Apr 24, 2024
Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M MT
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024 CI
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza; Development in Collaboration with GSK CI
CureVac N.V. and the University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel Cancer Vaccines CI
CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study MT
CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK CI
CureVac Reports Positive Phase 2 Results for mRNA Covid Vaccines Developed With GSK MT
GSK, CureVac Plan Late-stage Study of COVID-19 mRNA Vaccine Candidates MT
Dpa-AFX Overview: COMPANIES from 27.12.2023 - 15:15 DP
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10 MT
Chart CureVac N.V.
More charts
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.042 EUR
Average target price
8.728 EUR
Spread / Average Target
+186.89%
Consensus
  1. Stock Market
  2. Equities
  3. CVAC Stock
  4. News CureVac N.V.
  5. CureVac Begins Early Stage Portion of Investigational Vaccine Trial